IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Capital Investment Services of America Inc.

Capital Investment Services of America Inc. reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,754 shares of the company’s stock after selling 2,833 shares during the quarter. IDEXX Laboratories accounts for 1.9% of Capital Investment Services of America Inc.’s holdings, making the stock its 27th biggest position. Capital Investment Services of America Inc.’s holdings in IDEXX Laboratories were worth $19,579,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IDXX. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories in the first quarter valued at $26,000. Ridgewood Investments LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at $27,000. Institutional & Family Asset Management LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at $28,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC increased its stake in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Barclays reduced their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. JPMorgan Chase & Co. lowered their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Piper Sandler restated a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday. Finally, BTIG Research initiated coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $552.38.

IDEXX Laboratories Stock Up 0.1 %

Shares of NASDAQ IDXX traded up $0.54 during mid-day trading on Monday, reaching $417.82. The company had a trading volume of 206,028 shares, compared to its average volume of 489,335. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories, Inc. has a twelve month low of $404.74 and a twelve month high of $583.39. The stock’s 50 day moving average is $478.76 and its 200-day moving average is $487.19. The stock has a market capitalization of $34.39 billion, a PE ratio of 40.45, a price-to-earnings-growth ratio of 3.55 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same period in the prior year, the firm posted $2.53 EPS. The business’s revenue was up 6.6% compared to the same quarter last year. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.